Insight on Pharmaceuticals in Germany

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Report
Report

5EU: Pricing, Reimbursement and Regulatory Update

Datamonitor’s report 5EU: Pricing, Reimbursement, and Regulatory Update provides an overview of developments regarding healthcare reforms, drug regulation, and drug pricing and reimbursement in France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
28 Oct 2011 $1520
Buy
Report
Report

Biosimilars: Regulatory Update

Datamonitor’s report Biosimilars: Regulatory Update provides analysis on key developments in biosimilar regulations globally. It includes an overview of the background behind these events and popular strategic responses.

Published By Datamonitor
08 Dec 2011 $1520
Buy
Report
Report

Generics: Regulatory Update

Datamonitor’s report Generics: Regulatory Update provides an update of changes to generic regulations that occurred in the first half of 2011.

Published By Datamonitor
30 Aug 2011 $1520
Buy
Report
Report

Germany Pharmaceutical Market Overview – New pricing rules set to negatively impact drug sales both domestically and internationally

Overview of the German pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
15 Dec 2010 $3600
Buy
Report
Report

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality

Datamonitor provides an overview of and profiles key hemophilia A and B pipeline products launching in the near future in the US and five major EU markets (France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
12 Nov 2012 $2800
Buy
Report
Report

Market and Product Forecasts: Melanoma – Yervoy will continue to dominate as new approvals struggle to compete

This report and accompanying deliverable provides forecasts for melanoma drugs in the US and five major EU markets from 2012-21. Including in-depth analysis of the melanoma market in individual countries and dynamics of the key therapies.

Published By Datamonitor
23 Oct 2012 $6400
Buy
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Orphan Drug Trends

Datamonitor’s report Orphan Drug Trends provides an overview of orphan drug regulations in the major pharmaceutical markets, including pricing and reimbursement issues and an analysis of Big Pharma’s growing interest in orphan drugs.

Published By Datamonitor
25 Nov 2011 $2800
Buy
Report
Report

Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry

Global analysis of socio-demographic and economic trends, rising healthcare costs, intensifying cost-containment and regulatory pressures, the patent cliff as well insight into the pharmaceutical industry’s strategic responses to drive profitability.

Published By Datamonitor
20 May 2011 $1520
Buy
Report
Report

Pharmaceutical Key Trends 2011: Biosimilar Market Overview

Comparative analysis of biosimilar drivers and resistors, key players, market access, pricing, and future launches across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Published By Datamonitor
23 Feb 2011 $2800
Buy

« | 1 | 2 | » »|

No help is available.